

Ref: EPL/CS/SE/0056/2026

Date: July 11, 2026

To,

<b>National Stock Exchange of India Limited</b> Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	<b>BSE Limited</b> P J Towers, Dalal Street, Mumbai - 400 001
<b>Script Symbol: EMCURE</b>	<b>Scrip Code/Symbol: 544210/ EMCURE</b>

Dear Sir/Madam,

**Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Slump Sale of a Division of Gennova Biopharmaceuticals Limited, Subsidiary of the Company**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR Regulations"), we wish to inform you that Gennova Biopharmaceuticals Limited, a Subsidiary of the Company, has executed a Business Transfer Agreement for transfer of its mRNA business as a going concern on a slump sale basis to Immunoscrypt Life Science Private Limited on July 10, 2026.

The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the LODR Regulations are provided in **Annexure A**, enclosed herewith.

You are requested to take the above information on your records.

Thanking you,

**For Emcure Pharmaceuticals Limited**

**Amruta Yangelwar**  
**Company Secretary & Compliance Officer**  
**ICSI Membership Number: A25687**

*Encl: As above*

## **Emcure Pharmaceuticals Limited**

**Registered Office:** Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

**Phone Nos.:** +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

**E-mail:** corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

**Annexure A**

**Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:**

Sr. No	Particulars	Information
a)	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year	<p>The mRNA business (“Transferring business”) of Gennova Biopharmaceuticals Limited, Subsidiary of the Company (“Gennova”), has contributed as follows for FY 2025-26:</p> <p><b>Revenue:</b> Rs. 647.10 Million, representing 0.71% of consolidated revenue of the Company of Rs. 91,158.88 Million.</p> <p><b>Net worth:</b> Rs. 1,326.31 Million, representing 2.68% of consolidated net worth of the Company of Rs. 49,500.32 Million.</p>
b)	Date on which the agreement for sale has been entered into	July 10, 2026
c)	The expected date of completion of sale/disposal	Subject to fulfilment of conditions precedent and other terms set out in Business Transfer Agreement (“BTA”) and regulatory, statutory and other approvals, if any, the slump sale is expected to be completed by July 17, 2026 or such other date as may be mutually agreed between the parties.
d)	Consideration received from such sale/disposal	The Transferring business has been agreed to be transferred as a going concern on a slump sale basis for a lump sum cash consideration of Rs. 1,395 Million, in accordance with the terms of the BTA.
e)	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof	Immunoscript Life Science Private Limited (“Immunoscript”), a company incorporated under the Companies Act, 2013 having CIN-U72100PN2026PTC255053 with registered office situated at RH 14, Atul Excellency, Kaspate Wasti, Wakad, Sangavi, Pune - 411027, Maharashtra, India, and promoted by Dr. Sanjay Singh (formerly a Director of Gennova).

**Emcure Pharmaceuticals Limited**

**Registered Office:** Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

**Phone Nos.:** +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

**E-mail:** corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

		Immunoscript does not belong to the promoter/promoter group / group companies.
f)	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	Not applicable as on date of execution of BTA.
g)	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations	The slump sale does not form part of any Scheme of Arrangement and is being undertaken pursuant to the BTA. Regulation 37A of LODR Regulations is not applicable.
Additional details in case of slump sale, as applicable for amalgamation/merger are provided as under:		
h)	Name of the entity(ies) forming part of the slump sale, details in brief such as, size, turnover etc.	Turnover of Gennova - For FY 2025-26 as Rs. 4,917.42 Million.  Turnover of Immunoscript - Not Applicable as the company was incorporated in April 2026.
i)	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	As mentioned in point (f)
j)	Area of business of the entity(ies)	Gennova is involved in the business of research and development, manufacturing and marketing of biotechnology-based products.  Immunoscript's vision is to advance precision immunology in pursuit of a healthier world. They are integrating biological engineering, artificial intelligence, and scalable biomanufacturing technologies to accelerate the development of next-generation vaccines and advanced therapeutics for precision healthcare.

## Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060

E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251

## Emcure

k)	Rationale for slump sale	The transfer of mRNA business is part of Gennova's strategic initiative to reorganize its business operations and focus on core areas - research and development, manufacturing and marketing of biotechnology based products including biosimilars and adjacent therapeutic platforms.
l)	In case of cash consideration - amount or otherwise share exchange ratio	Cash consideration of Rs. 1,395 Million
m)	Brief details of change in shareholding pattern (if any) of listed entity	There will be no change in the shareholding pattern of the Company, pursuant to slump sale.

### Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060

E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251